おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Abivax
company
About
Abivax is a pioneering biotech company.
- 11 - 50
Highlights
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- €15M
- Industries
- Biotechnology
- Founded date
- Jan 1, 2013
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
€35M
Abivax has raised a total of
€35M
in funding over 2 rounds. Their latest funding was raised on
Oct 13, 2020 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 13, 2020 | Post-IPO Debt | €15M | 1 |
Kreos Capital
|
— | Detail |
| Jul 25, 2018 | Post-IPO Debt | €20M | 1 |
Kreos Capital
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
1
Abivax is funded by 1 investors.
Kreos Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Kreos Capital
|
Yes | Post-IPO Debt |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
